Prebiotics, Probiotics, and Synbiotics—A Research Hotspot for Pediatric Obesity
Abstract
:1. Introduction
2. Obesity, Microbiota, and Prebiotics, Probiotics, and Synbiotics
Reference (Author, Year) | Type of Study | Study Population | Objectives/Outcomes Measured | Prebiotics, Probiotics, and Synbiotic | Conclusions/Outcome |
---|---|---|---|---|---|
Vajro et al., 2011 [70] | Double-blind, placebo-controlled pilot study | n = 20 (10 probiotic/10 placebo) Age: 9–13 years BMI > 95th percentile | Effects of short-term probiotic on children with obesity-related liver disease | Lactobacillus rhamnosus GG (12 billion CFU/day) for 8 weeks | Decrease in alanine aminotransferase and in antipeptidoglycan polysaccharide antibodies, irrespective of changes in BMI z score and visceral fat. |
Gobel et al., 2012 [71] | Double-blind placebo-controlled trial | n = 50 (27 LS-33/23 placebo) Age: 12–15 years BMI > 95th percentile | Effect of Lactobacillus salivarius Ls-33 on biomarkers related to inflammation and metabolic syndrome (MS) | Lactobacillus salivarius Ls-33 (1010 CFU/day) for 12 weeks | No effects of probiotic strain Ls-33 on either the inflammatory markers or the markers of MS. |
Marcelo et al., 2022 [72] | Non-randomized controlled, prospective, double-blind interventional clinical trial | n = 44 (22 probiotic/22 placebo) Age: 8–17 years BMI > 95th percentile | Impact of probiotic supplementation therapy on anthropometric values and body composition | Lactobacillus rhamnosus IAL 1883 for 6 months | Supplementation with Lactobacillus rhamnosus IAL 1883 was not effective for weight loss or improving the body composition. |
Chen et al., 2022 [73] | Double-blind, randomized, placebo-controlled trial | n = 53 (27 probiotic/26 placebo) Age: 6–18 years BMI ≥ 85th percentile | Effects of multi-strain probiotics on the gut microbiota and weight control/BMI, LDLC, HDLC, adiponectin, leptin | Multi-strain probiotics consisting of Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, and Bifidobacterium animalis CP-9 for 12 weeks | Lowered serum TC, LDLC, TNF-α, and leptin, and reduced BMI. Elevation of adiponectin and HDLC. |
Verma et al., 2021 [74] | Randomized, double-blind, placebo-controlled pilot study | n = 15 (8 probiotic/7 placebo) Age: ≥13 years BMI ≥ 99th percentile | Effect of probiotics on gut microbiota and insulin resistance | Visbiome® containing probiotics (Lactobacillus plantarum DSM 24730, Lactobacillus plantarum DSM 24731, Lactobacillus plantarum DSM 24735, Lactobacillus plantarum DSM 24801, Lactobacillus paracasei DSM 24737, Lactobacillus salivarius DSM 24800, Lactobacillus delbrueckii DSM 25998, Bifidobacterium animalis DSM 24736, Bifidobacterium breve DSM 24732, and Pediococcus pentosaceus DSM 24734) two sachets/day 12 weeks | Improve fasting glucose levels and gut microbial composition (decrease F/B ratio). |
Karlsson et al., 2015 [75] | Double-blind, randomized, placebo-controlled intervention trial | n = 120 (58 probiotic/62 placebo) Age: 8–9 years | Long-term effect of feeding with Lactobacillus paracasei F19 (LF19) on body composition, growth, and metabolic markers (TC, HDLC, apo A-1, apo B, TG, glucose, AST, ALT, S-insuline) | Administration of Lactobacillus paracasei F19 from 4 to 13 months of age, 1 × 108 CFU/at least once daily | LF19 had no modulatory effect on growth (BMI z-score, sagittal abdominal diameter, fat-free mass, fat mass index, truncal fat %, android or gynoid fat %) or body composition at school age and no long-term impact on metabolic markers. |
Luoto et al., 2010 [77] | Randomized, double-blind, prospective follow-up study | n = 113 (77 probiotics/82 placebo) Age: 2 weeks–10 years | Impact of perinatal probiotic intervention on childhood growth patterns and the development of overweight during a 10-year follow-up | Administration of Lactobacillus rhamnosus (1 × 1010 CFU) in mothers 4 weeks before delivery and in infants until the age of 6 months | Early probiotics may restrain excessive weight gain during the first years of life. |
Saros et al., 2023 [81] | Double-blind, placebo-controlled randomized trial | n = 439 pregnant women BMI ≥ 25 kg/m2 pre-pregnancy n = 330 children Age ≤ 2 years 4 parallel groups: fish oil + placebo, probiotics + placebo, probiotics + fish oil, placebo + placebo | Fish oil and/or probiotic effect in pregnant women with overweight or obesity on the tendency of their 24-month-old children to become overweight | Administration of Lactobacillus rhamnosus HN001 and Bifidobacterium animalis ssp. lactis 420 (1010 CFU/day) alone or combined with fish oil during pregnancy and in the first 6 months postpartum | Decreased the risk of obesity in their children at the age of 24 months. |
Nicolucci et al., 2017 [52] | Randomized, double-blind, placebo-controlled trial | n = 42 (22 OI/20 placebo) Age: 7–12 years BMI ≥ 85th percentile | Effects of prebiotics on body composition, markers of inflammation, bile acids in fecal samples, and composition of the intestinal microbiota | Administration of oligofructose-enriched inulin (OI) 8 g/day for 16 weeks | OI administration reduces body weight z-score, percent body fat, percent trunk fat, serum interleukin 6, and triglycerides; increase fecal Bifidobacterium spp. |
Atazadegan et al., 2023 [86] | Randomized double-blind, placebo-controlled trial | n = 60 (30 synbiotic/30 control) Age: 8–18 years BMI ≥ 85th percentile | Effect of synbiotic on anthropometric indices and body composition | Combination of Lactobacillus indicus 6 × 109 colony forming units (CFU) and Lactobacillus coagulans 6 × 109 CFU twice a day as probiotics combined with short-chain fructo-oligosaccharide for 8 weeks | A significant reduction of waist–height ratio. |
Ipar et al., 2015 [87] | Open-label, randomised, controlled study | n = 86 (43 synbiotic/43 control) Age: 5–17 years BMI > 95th percentile | Effects of a synbiotic on anthropometric measurements, lipid profile, and oxidative stress parameters | A probiotic mixture including Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, and Enterococcus faecium, combined with fructo-oligosaccharydes for one month | Decrease of weight and BMI. Decrease of serum total cholesterol, low density lipoprotein cholesterol and total oxidative stress levels. |
Kilic Yildirim et al., 2022 [89] | Randomized, double-blind, placebo-controlled trial | n = 61 (30 synbiotic/31 placebo) Age: 8–17 years BMI > 95th percentile | Effects of synbiotic on anthropometric measurements, glucose metabolism, and lipid parameters | Synbiotic including Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum, and Enterococcus faecium, combined with fructo-oligosaccharides for 12 weeks vs. placebo. | Decreased weight, BMI, and anthropometric parameters. |
3. Implications in Obesity-Related Complications
3.1. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
3.2. Metabolic Syndrome and Insulin Resistance
Reference (Author, Year) | Type of Study | Study Population | Objectives | Prebiotics, Probiotics and Synbiotic | Obesity | Conclusions | ||
---|---|---|---|---|---|---|---|---|
NAFLD/ NASH | Metabolic Syndrome | Insulin Resistance | ||||||
Loomba et al., 2017 [97] | Prospective study | n = 86 NAFLD Age: >18 years | Identification of fecal-microbiome-derived metagenomic signature to detect advanced fibrosis in NAFLD | − | + | − | − | Escherichia, Enterobacteria, Proteobacteria, and Bacteroides are more commonly found in patients with NASH. |
Vajro et al., 2011 [70] | Double-blind, placebo-controlled pilot study | n = 20 (10 probiotic/10 placebo) Age: 9–13 years BMI > 95th percentile | Effects of short-term probiotic on children with obesity-related liver disease | Lactobacillus rhamnosus GG (12 billion CFU/day) for 8 weeks | + | − | − | Lactobacillus rhamnosus decrease of ALT in children with hepatic steatosis. |
Alisi et al., 2014 [98] | Parallel-arm double-blind trial | n = 44 (22 VSL#3/22 placebo) Age: 9–13 years BMI > 85th percentile Obese + NAFLD | Effect of VSL#3 on structural improvement of FL in obese children with biopsy-proven NAFLD | VSL#3 is a mixture of Streptococcus thermophilus, Bifidobacteria breve, Bifidobacteria infantis, Bifidobacteria longum, Lactobacillus acidophilus, L. plantarum, L. paracasei, and L. delbrueckii subsp. bulgaricus 1 sachet/day of VSL#3 < 10 years, 2 sachets/day of VSL#3 > 10 years vs. placebo for 4 months | + | − | − | Streptococcus thermophilus, lactobacilli, and bifidobacteria might improve the ultrasound of the liver after 4 months of administration. |
Famouri et al., 2017 [99] | Randomized, triple-blind, placebo-controlled trial | n = 64 (32 probiotic/32 placebo) Age: 10–18 years BMI > 85th percentile Obese + NAFLD | Effects of probiotics on NAFLD in obese children and adolescents | Lactobacillus acidophilus ATCC B3208, 3 × 109 CFU; Bifidobacterium lactis DSMZ 32269, 6 × 109 CFU; Bifidobacterium bifidum ATCC SD6576, 2 × 109 CFU; Lactobacillus rhamnosus DSMZ 21690, 2 × 109 CFU 1 caps/day vs. placebo for 12 weeks | + | − | − | Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, and Bifidobacterium bifidum for 12 weeks in obese children → improving AST, ALT level, liver steatosis, and lipid profile. |
Rodrigo et al., 2022 [100] | Double-blind, randomized, placebo-controlled trial | n = 84 (43 probiotic/41 placebo) Age: 5–15 years BMI > +2 standard deviation for age AST/ALT < 1 Hepatic steatosis, grade I to III | Effects of probiotics on metabolic derangement in obese children with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). | BioKult 14 strain probiotic capsule: 1 caps/day < 12 years, 2 caps/day ≥ 12 years 6 months | + | − | − | Significant decrease of body mass index irrespective of the group which received probiotic with 14 bacterial strains or the placebo group. |
Kilic Yildirim et al., 2022 [89] | Randomized, double-blind, placebo-controlled trial | n = 61 (30 synbiotic/31 placebo) Age: 8–17 years BMI > 95th percentile | Effects of synbiotic on anthropometric measurements, glucose metabolism, and lipid parameters | Synbiotic including Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum, and Enterococcus faecium, combined with fructo-oligosaccharides for 12 weeks vs. placebo. | No impact on NAFLD | − | − | Synbiotics (Bifidobacterium longum, Bifidobacterium bifidum, Enterococcus faecium, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, and fructo-oligosaccharides) → no impact on NAFLD and no effect on lipid parameters and glucose metabolism. |
Karlsson et al., 2015 [75,77] | Double-blind, randomized, placebo-controlled intervention trial | n = 120 (58 probiotic/62 placebo) Age: 8–9 years | Long-term effect of feeding with Lactobacillus paracasei F19 (LF19) on body composition, growth, and metabolic markers (TC, HDLC, apo A-1, apo B, TG, glucose, AST, ALT, S-insuline) | Administration of Lactobacillus paracasei F19 from 4 to 13 months of age, 1 × 108 CFU/at least once daily | − | No effect | − | Lactobacillus rhamnosus GG and Lactobacillus paracasei ssp. F19 → no effect on metabolic syndrome. |
Benítez-Páez et al., 2020 [110] | Cross-sectional study | n= 51 (16 lean/20 obese/15 obese + IR Age: 5–17 years BMI z-score of ≥2 SD | Study of gut microbiota profile of lean and obese children with/without insulin resistance and associations with specific obesity-related complications and metabolic inflammation | − | − | + | − | Blautia species → modulating glucose metabolism in children. Depletion of B. luti and B. wexlerae species occur in obesity and lead to metabolic inflammation and insulin resistance. |
Solito et al., 2023 [114] | Cross-over, double-blind, randomized control trial | n= 101 (51 probiotic/50 placebo) obese+ IR Age: 6–18 years | Impact of a probiotic supplementation in pediatric obesity on weight, metabolic alterations, and selected gut microbial groups | 2 × 109 CFU/AFU/day of Bifidobacterium breve BR03 (DSM 16604) and B. breve B632 (DSM 24706) or placebo for 8 weeks | − | Positive effect | Improve insulin sensitivity | Bifidobacterium breve B632 and Bifidobacterium breve BR03 administered for 8 weeks → improvement in insulin sensitivity and decreased body mass index and waist circumference. |
Chen et al., 2022 [73] | Double-blind, randomized, placebo-controlled trial | n = 53 (27 probiotic/26 placebo) | Effects of multi-strain probiotics on the gut microbiota and weight control/BMI, LDLC, HDLC, adiponectin, and leptin | Multi-strain probiotics consisting of Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, and Bifidobacterium animalis CP-9 for 12 weeks | − | Positive effect | − | Lactobacillus salivarius and Bifidobacterium animalis on a pediatric population from China → significantly reduce body mass index in obese children and a significant improvement of blood lipid content |
Sanchis-Chordà et al., 2019 [115] | Prospective analytical intervention study | n = 56 (28 probiotic/28 control Age: 7–16 years obese + IR BMI z-score of ≥2 SD | Effect of Bifidobacterium pseudocatenulatum CECT 7765 on inflammatory cytokines, cardiometabolic risk factors, and gut microbiota composition in obese children with IR | B. pseudocatenulatum (CECT 7765) 1 × 109–1 × 1010 CFU per day for 91 days vs. control | − | + | + | Bifidobacterium pseudocatenulatum CECT 7765 → determine lower levels of C-reactive protein and monocyte chemoattractant protein-1 and elevated levels of high-density lipoprotein cholesterol and omentin-1 → anti-inflammatory effect |
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Strauss, R.S.; Pollack, H.A. Epidemic Increase in Childhood Overweight, 1986–1998. JAMA 2001, 286, 2845–2848. [Google Scholar] [CrossRef]
- GBD 2015 Obesity Collaborators; Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Moradi-Lakeh, M.; et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med. 2017, 377, 13–27. [Google Scholar] [CrossRef]
- Han, J.C.; Lawlor, D.A.; Kimm, S.Y.S. Childhood Obesity. Lancet 2010, 375, 1737–1748. [Google Scholar] [CrossRef]
- Zhao, X.; Gang, X.; Liu, Y.; Sun, C.; Han, Q.; Wang, G. Using Metabolomic Profiles as Biomarkers for Insulin Resistance in Childhood Obesity: A Systematic Review. J. Diabetes Res. 2016, 2016, 8160545. [Google Scholar] [CrossRef] [PubMed]
- Concepcion, J.; Chen, K.; Saito, R.; Gangoiti, J.; Mendez, E.; Nikita, M.E.; Barshop, B.A.; Natarajan, L.; Sharma, K.; Kim, J.J. Identification of Pathognomonic Purine Synthesis Biomarkers by Metabolomic Profiling of Adolescents with Obesity and Type 2 Diabetes. PLoS ONE 2020, 15, e0234970. [Google Scholar] [CrossRef] [PubMed]
- Bosco, A.; Loi, M.; Pinna, G.; Pintus, R.; Fanos, V.; Dessì, A. Childhood Obesity and the Cryptic Language of the Microbiota: Metabolomics’ Upgrading. Metabolites 2023, 13, 414. [Google Scholar] [CrossRef]
- Mastrangelo, A.; Martos-Moreno, G.Á.; García, A.; Barrios, V.; Rupérez, F.J.; Chowen, J.A.; Barbas, C.; Argente, J. Insulin Resistance in Prepubertal Obese Children Correlates with Sex-Dependent Early Onset Metabolomic Alterations. Int. J. Obes. 2016, 40, 1494–1502. [Google Scholar] [CrossRef] [PubMed]
- Ten, S.; Maclaren, N. Insulin Resistance Syndrome in Children. J. Clin. Endocrinol. Metab. 2004, 89, 2526–2539. [Google Scholar] [CrossRef]
- Butte, N.F.; Liu, Y.; Zakeri, I.F.; Mohney, R.P.; Mehta, N.; Voruganti, V.S.; Göring, H.; Cole, S.A.; Comuzzie, A.G. Global Metabolomic Profiling Targeting Childhood Obesity in the Hispanic Population. Am. J. Clin. Nutr. 2015, 102, 256–267. [Google Scholar] [CrossRef]
- Barlow, S.E.; Dietz, W.H. Obesity Evaluation and Treatment: Expert Committee Recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998, 102, E29. [Google Scholar] [CrossRef]
- Cardel, M.I.; Atkinson, M.A.; Taveras, E.M.; Holm, J.-C.; Kelly, A.S. Obesity Treatment Among Adolescents: A Review of Current Evidence and Future Directions. JAMA Pediatr. 2020, 174, 609–617. [Google Scholar] [CrossRef] [PubMed]
- Berger, N.A. Young Adult Cancer: Influence of the Obesity Pandemic. Obesity 2018, 26, 641–650. [Google Scholar] [CrossRef] [PubMed]
- Wahl, S.; Yu, Z.; Kleber, M.; Singmann, P.; Holzapfel, C.; He, Y.; Mittelstrass, K.; Polonikov, A.; Prehn, C.; Römisch-Margl, W.; et al. Childhood Obesity Is Associated with Changes in the Serum Metabolite Profile. Obes. Facts 2012, 5, 660–670. [Google Scholar] [CrossRef] [PubMed]
- Borka Balas, R.; Meliț, L.E.; Sarkozi, D.; Ghiga, D.V.; Mărginean, C.O. Cyberbullying in Teenagers—A True Burden in the Era of Online Socialization. Medicine 2023, 102, e34051. [Google Scholar] [CrossRef]
- WHO|Overweight and Obesity. Available online: http://www.who.int/gho/ncd/risk_factors/overweight_adolescents_text/en/ (accessed on 27 March 2021).
- Mǎrginean, C.O.; Mǎrginean, C.; Meliţ, L.E. New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview. Front. Pediatr. 2018, 6, 271. [Google Scholar] [CrossRef] [PubMed]
- Rugină, C.; Mărginean, C.O.; Meliţ, L.E.; Giga, D.V.; Modi, V.; Mărginean, C. Relationships between Excessive Gestational Weight Gain and Energy and Macronutrient Intake in Pregnant Women. J. Int. Med. Res. 2020, 48, 300060520933808. [Google Scholar] [CrossRef]
- Mărginean, C.; Mărginean, C.O.; Bănescu, C.; Meliţ, L.; Tripon, F.; Iancu, M. Impact of Demographic, Genetic, and Bioimpedance Factors on Gestational Weight Gain and Birth Weight in a Romanian Population: A Cross-Sectional Study in Mothers and Their Newborns: The Monebo Study (STROBE-Compliant Article). Medicine 2016, 95, e4098. [Google Scholar] [CrossRef] [PubMed]
- Aggarwal, B.; Jain, V. Obesity in Children: Definition, Etiology and Approach. Indian J. Pediatr. 2018, 85, 463–471. [Google Scholar] [CrossRef]
- Sender, R.; Fuchs, S.; Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016, 14, e1002533. [Google Scholar] [CrossRef]
- Harris, K.; Kassis, A.; Major, G.; Chou, C.J. Is the Gut Microbiota a New Factor Contributing to Obesity and Its Metabolic Disorders? J. Obes. 2012, 2012, 879151. [Google Scholar] [CrossRef]
- Blaser, M.J.; Devkota, S.; McCoy, K.D.; Relman, D.A.; Yassour, M.; Young, V.B. Lessons Learned from the Prenatal Microbiome Controversy. Microbiome 2021, 9, 8. [Google Scholar] [CrossRef] [PubMed]
- Walter, J.; Hornef, M.W. A Philosophical Perspective on the Prenatal in Utero Microbiome Debate. Microbiome 2021, 9, 5. [Google Scholar] [CrossRef]
- Aagaard, K.; Ma, J.; Antony, K.M.; Ganu, R.; Petrosino, J.; Versalovic, J. The Placenta Harbors a Unique Microbiome. Sci. Transl. Med. 2014, 6, 237ra65. [Google Scholar] [CrossRef]
- Bassols, J.; Serino, M.; Carreras-Badosa, G.; Burcelin, R.; Blasco-Baque, V.; Lopez-Bermejo, A.; Fernandez-Real, J.-M. Gestational Diabetes Is Associated with Changes in Placental Microbiota and Microbiome. Pediatr. Res. 2016, 80, 777–784. [Google Scholar] [CrossRef]
- Zheng, J.; Xiao, X.; Zhang, Q.; Mao, L.; Yu, M.; Xu, J.; Wang, T. The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study. Front. Physiol. 2017, 8, 675. [Google Scholar] [CrossRef] [PubMed]
- Hu, J.; Nomura, Y.; Bashir, A.; Fernandez-Hernandez, H.; Itzkowitz, S.; Pei, Z.; Stone, J.; Loudon, H.; Peter, I. Diversified Microbiota of Meconium Is Affected by Maternal Diabetes Status. PLoS ONE 2013, 8, e78257. [Google Scholar] [CrossRef]
- Rodríguez, J.M.; Murphy, K.; Stanton, C.; Ross, R.P.; Kober, O.I.; Juge, N.; Avershina, E.; Rudi, K.; Narbad, A.; Jenmalm, M.C.; et al. The Composition of the Gut Microbiota throughout Life, with an Emphasis on Early Life. Microb. Ecol. Health Dis. 2015, 26, 26050. [Google Scholar] [CrossRef]
- Meliț, L.E.; Mărginean, C.O.; Săsăran, M.O. The Yin-Yang Concept of Pediatric Obesity and Gut Microbiota. Biomedicines 2022, 10, 645. [Google Scholar] [CrossRef]
- Vangay, P.; Ward, T.; Gerber, J.S.; Knights, D. Antibiotics, Pediatric Dysbiosis, and Disease. Cell Host Microbe 2015, 17, 553–564. [Google Scholar] [CrossRef] [PubMed]
- Beller, L.; Deboutte, W.; Falony, G.; Vieira-Silva, S.; Tito, R.Y.; Valles-Colomer, M.; Rymenans, L.; Jansen, D.; Van Espen, L.; Papadaki, M.I.; et al. Successional Stages in Infant Gut Microbiota Maturation. mBio 2021, 12, e0185721. [Google Scholar] [CrossRef] [PubMed]
- Dominguez-Bello, M.G.; Blaser, M.J.; Ley, R.E.; Knight, R. Development of the Human Gastrointestinal Microbiota and Insights from High-Throughput Sequencing. Gastroenterology 2011, 140, 1713–1719. [Google Scholar] [CrossRef] [PubMed]
- Kumbhare, S.V.; Patangia, D.V.V.; Patil, R.H.; Shouche, Y.S.; Patil, N.P. Factors Influencing the Gut Microbiome in Children: From Infancy to Childhood. J. Biosci. 2019, 44, 49. [Google Scholar] [CrossRef]
- Azad, M.B.; Konya, T.; Maughan, H.; Guttman, D.S.; Field, C.J.; Chari, R.S.; Sears, M.R.; Becker, A.B.; Scott, J.A.; Kozyrskyj, A.L.; et al. Gut Microbiota of Healthy Canadian Infants: Profiles by Mode of Delivery and Infant Diet at 4 Months. CMAJ 2013, 185, 385–394. [Google Scholar] [CrossRef]
- Rutayisire, E.; Huang, K.; Liu, Y.; Tao, F. The Mode of Delivery Affects the Diversity and Colonization Pattern of the Gut Microbiota during the First Year of Infants’ Life: A Systematic Review. BMC Gastroenterol. 2016, 16, 86. [Google Scholar] [CrossRef]
- Song, S.J.; Dominguez-Bello, M.G.; Knight, R. How Delivery Mode and Feeding Can Shape the Bacterial Community in the Infant Gut. CMAJ 2013, 185, 373–374. [Google Scholar] [CrossRef] [PubMed]
- Jakobsson, H.E.; Abrahamsson, T.R.; Jenmalm, M.C.; Harris, K.; Quince, C.; Jernberg, C.; Björkstén, B.; Engstrand, L.; Andersson, A.F. Decreased Gut Microbiota Diversity, Delayed Bacteroidetes Colonisation and Reduced Th1 Responses in Infants Delivered by Caesarean Section. Gut 2014, 63, 559–566. [Google Scholar] [CrossRef] [PubMed]
- Kuhle, S.; Woolcott, C.G. Caesarean Section Is Associated with Offspring Obesity in Childhood and Young Adulthood. BMJ Evid.-Based Med. 2017, 22, 111. [Google Scholar] [CrossRef] [PubMed]
- Rutayisire, E.; Wu, X.; Huang, K.; Tao, S.; Chen, Y.; Tao, F. Cesarean Section May Increase the Risk of Both Overweight and Obesity in Preschool Children. BMC Pregnancy Childbirth 2016, 16, 338. [Google Scholar] [CrossRef]
- Thurl, S.; Munzert, M.; Henker, J.; Boehm, G.; Müller-Werner, B.; Jelinek, J.; Stahl, B. Variation of Human Milk Oligosaccharides in Relation to Milk Groups and Lactational Periods. Br. J. Nutr. 2010, 104, 1261–1271. [Google Scholar] [CrossRef]
- Cabrera-Rubio, R.; Collado, M.C.; Laitinen, K.; Salminen, S.; Isolauri, E.; Mira, A. The Human Milk Microbiome Changes over Lactation and Is Shaped by Maternal Weight and Mode of Delivery. Am. J. Clin. Nutr. 2012, 96, 544–551. [Google Scholar] [CrossRef]
- Collado, M.C.; Laitinen, K.; Salminen, S.; Isolauri, E. Maternal Weight and Excessive Weight Gain during Pregnancy Modify the Immunomodulatory Potential of Breast Milk. Pediatr. Res. 2012, 72, 77–85. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.; Osadchiy, V.; Mayer, E.A. Brain-Gut-Microbiome Interactions in Obesity and Food Addiction. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 655–672. [Google Scholar] [CrossRef]
- Bergström, A.; Skov, T.H.; Bahl, M.I.; Roager, H.M.; Christensen, L.B.; Ejlerskov, K.T.; Mølgaard, C.; Michaelsen, K.F.; Licht, T.R. Establishment of Intestinal Microbiota during Early Life: A Longitudinal, Explorative Study of a Large Cohort of Danish Infants. Appl. Environ. Microbiol. 2014, 80, 2889–2900. [Google Scholar] [CrossRef] [PubMed]
- Nakayama, J.; Yamamoto, A.; Palermo-Conde, L.A.; Higashi, K.; Sonomoto, K.; Tan, J.; Lee, Y.-K. Impact of Westernized Diet on Gut Microbiota in Children on Leyte Island. Front. Microbiol. 2017, 8, 197. [Google Scholar] [CrossRef] [PubMed]
- Mărginean, C.; Meliț, L.; Ghiga, D.; Mărginean, M. Early Inflammatory Status Related to Pediatric Obesity (STROBE Compliant Article). Front. Pediatr. 2019, 7, 241. [Google Scholar] [CrossRef]
- Blüher, S.; Schwarz, P. Metabolically Healthy Obesity from Childhood to Adulthood—Does Weight Status Alone Matter? Metabolism 2014, 63, 1084–1092. [Google Scholar] [CrossRef]
- Wan Mohd Zin, R.M.; Jalaludin, M.Y.; Yahya, A.; Nur Zati Iwani, A.K.; Md Zain, F.; Hong, J.Y.H.; Mokhtar, A.H.; Wan Mohamud, W.N. Prevalence and Clinical Characteristics of Metabolically Healthy Obese versus Metabolically Unhealthy Obese School Children. Front. Endocrinol. 2022, 13, 971202. [Google Scholar] [CrossRef]
- Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest. Nature 2006, 444, 1027–1031. [Google Scholar] [CrossRef] [PubMed]
- Meliț, L.E.; Mărginean, C.O.; Mărginean, C.D.; Săsăran, M.O. The Peculiar Trialogue between Pediatric Obesity, Systemic Inflammatory Status, and Immunity. Biology 2021, 10, 512. [Google Scholar] [CrossRef]
- Parnell, J.A.; Reimer, R.A. Weight Loss during Oligofructose Supplementation Is Associated with Decreased Ghrelin and Increased Peptide YY in Overweight and Obese Adults. Am. J. Clin. Nutr. 2009, 89, 1751–1759. [Google Scholar] [CrossRef]
- Nicolucci, A.C.; Hume, M.P.; Martínez, I.; Mayengbam, S.; Walter, J.; Reimer, R.A. Prebiotics Reduce Body Fat and Alter Intestinal Microbiota in Children Who Are Overweight or With Obesity. Gastroenterology 2017, 153, 711–722. [Google Scholar] [CrossRef] [PubMed]
- Zhao, L.; Zhang, F.; Ding, X.; Wu, G.; Lam, Y.Y.; Wang, X.; Fu, H.; Xue, X.; Lu, C.; Ma, J.; et al. Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2 Diabetes. Science 2018, 359, 1151–1156. [Google Scholar] [CrossRef] [PubMed]
- Pérez-Losada, M.; Castro-Nallar, E.; Bendall, M.L.; Freishtat, R.J.; Crandall, K.A. Dual Transcriptomic Profiling of Host and Microbiota during Health and Disease in Pediatric Asthma. PLoS ONE 2015, 10, e0131819. [Google Scholar] [CrossRef] [PubMed]
- Indiani, C.M.D.S.P.; Rizzardi, K.F.; Castelo, P.M.; Ferraz, L.F.C.; Darrieux, M.; Parisotto, T.M. Childhood Obesity and Firmicutes/Bacteroidetes Ratio in the Gut Microbiota: A Systematic Review. Child. Obes. 2018, 14, 501–509. [Google Scholar] [CrossRef]
- Edwards, P.T.; Kashyap, P.C.; Preidis, G.A. Microbiota on Biotics: Probiotics, Prebiotics, and Synbiotics to Optimize Growth and Metabolism. Am. J. Physiol.-Gastrointest. Liver Physiol. 2020, 319, G382–G390. [Google Scholar] [CrossRef] [PubMed]
- Isanaka, S.; Langendorf, C.; Berthé, F.; Gnegne, S.; Li, N.; Ousmane, N.; Harouna, S.; Hassane, H.; Schaefer, M.; Adehossi, E.; et al. Routine Amoxicillin for Uncomplicated Severe Acute Malnutrition in Children. N. Engl. J. Med. 2016, 374, 444–453. [Google Scholar] [CrossRef]
- Nobel, Y.R.; Cox, L.M.; Kirigin, F.F.; Bokulich, N.A.; Yamanishi, S.; Teitler, I.; Chung, J.; Sohn, J.; Barber, C.M.; Goldfarb, D.S.; et al. Metabolic and Metagenomic Outcomes from Early-Life Pulsed Antibiotic Treatment. Nat. Commun. 2015, 6, 7486. [Google Scholar] [CrossRef]
- Stark, C.M.; Susi, A.; Emerick, J.; Nylund, C.M. Antibiotic and Acid-Suppression Medications during Early Childhood Are Associated with Obesity. Gut 2019, 68, 62–69. [Google Scholar] [CrossRef]
- Barengolts, E. Gut Microbiota, Prebiotics, Probiotics, and Synbiotics in Management of Obesity and Prediabets: Review of Randomized Controlled Trials. Endocr. Pract. 2016, 22, 1224–1234. [Google Scholar] [CrossRef] [PubMed]
- Park, D.-Y.; Ahn, Y.-T.; Huh, C.-S.; McGregor, R.A.; Choi, M.-S. Dual Probiotic Strains Suppress High Fructose-Induced Metabolic Syndrome. World J. Gastroenterol. 2013, 19, 274–283. [Google Scholar] [CrossRef] [PubMed]
- Sankararaman, S.; Noriega, K.; Velayuthan, S.; Sferra, T.; Martindale, R. Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders. Curr. Gastroenterol. Rep. 2023, 25, 31–44. [Google Scholar] [CrossRef]
- Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.S.; Cani, P.D.; et al. Expert Consensus Document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 491–502. [Google Scholar] [CrossRef]
- Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. Expert Consensus Document. The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506–514. [Google Scholar] [CrossRef]
- Swanson, K.S.; Gibson, G.R.; Hutkins, R.; Reimer, R.A.; Reid, G.; Verbeke, K.; Scott, K.P.; Holscher, H.D.; Azad, M.B.; Delzenne, N.M.; et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Synbiotics. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 687–701. [Google Scholar] [CrossRef]
- Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J.P.; Druart, C.; Bindels, L.B.; Guiot, Y.; Derrien, M.; Muccioli, G.G.; Delzenne, N.M.; et al. Cross-Talk between Akkermansia Muciniphila and Intestinal Epithelium Controls Diet-Induced Obesity. Proc. Natl. Acad. Sci. USA 2013, 110, 9066–9071. [Google Scholar] [CrossRef] [PubMed]
- Plovier, H.; Everard, A.; Druart, C.; Depommier, C.; Van Hul, M.; Geurts, L.; Chilloux, J.; Ottman, N.; Duparc, T.; Lichtenstein, L.; et al. A Purified Membrane Protein from Akkermansia Muciniphila or the Pasteurized Bacterium Improves Metabolism in Obese and Diabetic Mice. Nat. Med. 2017, 23, 107–113. [Google Scholar] [CrossRef] [PubMed]
- Depommier, C.; Everard, A.; Druart, C.; Plovier, H.; Van Hul, M.; Vieira-Silva, S.; Falony, G.; Raes, J.; Maiter, D.; Delzenne, N.M.; et al. Supplementation with Akkermansia Muciniphila in Overweight and Obese Human Volunteers: A Proof-of-Concept Exploratory Study. Nat. Med. 2019, 25, 1096–1103. [Google Scholar] [CrossRef] [PubMed]
- Goodrich, J.K.; Waters, J.L.; Poole, A.C.; Sutter, J.L.; Koren, O.; Blekhman, R.; Beaumont, M.; Van Treuren, W.; Knight, R.; Bell, J.T.; et al. Human Genetics Shape the Gut Microbiome. Cell 2014, 159, 789–799. [Google Scholar] [CrossRef]
- Vajro, P.; Mandato, C.; Licenziati, M.R.; Franzese, A.; Vitale, D.F.; Lenta, S.; Caropreso, M.; Vallone, G.; Meli, R. Effects of Lactobacillus Rhamnosus Strain GG in Pediatric Obesity-Related Liver Disease. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 740–743. [Google Scholar] [CrossRef]
- Gøbel, R.J.; Larsen, N.; Jakobsen, M.; Mølgaard, C.; Michaelsen, K.F. Probiotics to Adolescents with Obesity: Effects on Inflammation and Metabolic Syndrome. J. Pediatr. Gastroenterol. Nutr. 2012, 55, 673–678. [Google Scholar] [CrossRef]
- Marcelo, T.L.P.; Pellicciari, C.R.; Artioli, T.O.; Leiderman, D.B.D.; Gradinar, A.L.T.; Mimica, M.; Kochi, C. Probiotic Therapy Outcomes in Body Composition of Children and Adolescent with Obesity, a Nonrandomized Controlled Trial. Arch. Endocrinol. Metab. 2022, 66, 815–822. [Google Scholar] [CrossRef]
- Chen, A.-C.; Fang, T.-J.; Ho, H.-H.; Chen, J.-F.; Kuo, Y.-W.; Huang, Y.-Y.; Tsai, S.-Y.; Wu, S.-F.; Lin, H.-C.; Yeh, Y.-T. A Multi-Strain Probiotic Blend Reshaped Obesity-Related Gut Dysbiosis and Improved Lipid Metabolism in Obese Children. Front. Nutr. 2022, 9, 922993. [Google Scholar] [CrossRef]
- Verma, A.; Nelson, M.T.; DePaolo, W.R.; Hampe, C.; Roth, C.L. A Randomized Double-Blind Placebo Controlled Pilot Study of Probiotics in Adolescents with Severe Obesity. J. Diabetes Metab. Disord. 2021, 20, 1289–1300. [Google Scholar] [CrossRef] [PubMed]
- Karlsson Videhult, F.; Öhlund, I.; Stenlund, H.; Hernell, O.; West, C.E. Probiotics during Weaning: A Follow-up Study on Effects on Body Composition and Metabolic Markers at School Age. Eur. J. Nutr. 2015, 54, 355–363. [Google Scholar] [CrossRef] [PubMed]
- Dror, T.; Dickstein, Y.; Dubourg, G.; Paul, M. Microbiota Manipulation for Weight Change. Microb. Pathog. 2017, 106, 146–161. [Google Scholar] [CrossRef] [PubMed]
- Luoto, R.; Kalliomäki, M.; Laitinen, K.; Isolauri, E. The Impact of Perinatal Probiotic Intervention on the Development of Overweight and Obesity: Follow-up Study from Birth to 10 Years. Int. J. Obes. 2010, 34, 1531–1537. [Google Scholar] [CrossRef]
- Mărginean, C.; Mărginean, C.O.; Iancu, M.; Szabo, B.; Cucerea, M.; Melit, L.E.; Crauciuc, A.; Bănescu, C. The Role of TGF-B1 869 T>C and PPAR Γ2 34 C>G Polymorphisms, Fat Mass, and Anthropometric Characteristics in Predicting Childhood Obesity at Birth: A Cross-Sectional Study According the Parental Characteristics and Newborn’s Risk for Child. Obes.ity (the Newborns Obesity’s Risk) NOR Study. Medicine 2016, 95, e4265. [Google Scholar] [CrossRef]
- Mărginean, C.; Mărginean, C.O.; Iancu, M.; Meliţ, L.E.; Tripon, F.; Bănescu, C. The FTO Rs9939609 and LEPR Rs1137101 Mothers-Newborns Gene Polymorphisms and Maternal Fat Mass Index Effects on Anthropometric Characteristics in Newborns: A Cross-Sectional Study on Mothers-Newborns Gene Polymorphisms-The FTO-LEPR Study (STROBE-Compliant Article). Medicine 2016, 95, e5551. [Google Scholar] [CrossRef]
- Mărginean, C.O.; Mărginean, C.; Bănescu, C.; Meliţ, L.E.; Tripon, F.; Iancu, M. The Relationship between MMP9 and ADRA2A Gene Polymorphisms and Mothers-Newborns’ Nutritional Status: An Exploratory Path Model (STROBE Compliant Article). Pediatr. Res. 2019, 85, 822–829. [Google Scholar] [CrossRef]
- Saros, L.; Vahlberg, T.; Koivuniemi, E.; Houttu, N.; Niinikoski, H.; Tertti, K.; Laitinen, K. Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children. J. Pediatr. Gastroenterol. Nutr. 2023, 76, 218–226. [Google Scholar] [CrossRef]
- Vähämiko, S.; Laiho, A.; Lund, R.; Isolauri, E.; Salminen, S.; Laitinen, K. The Impact of Probiotic Supplementation during Pregnancy on DNA Methylation of Obesity-Related Genes in Mothers and Their Children. Eur. J. Nutr. 2019, 58, 367–377. [Google Scholar] [CrossRef] [PubMed]
- Oddi, S.; Huber, P.; Rocha Faria Duque, A.L.; Vinderola, G.; Sivieri, K. Breast-Milk Derived Potential Probiotics as Strategy for the Management of Childhood Obesity. Food Res. Int. 2020, 137, 109673. [Google Scholar] [CrossRef] [PubMed]
- Markowiak, P.; Śliżewska, K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017, 9, 1021. [Google Scholar] [CrossRef]
- Gurry, T. Synbiotic Approaches to Human Health and Well-Being. Microb. Biotechnol. 2017, 10, 1070–1073. [Google Scholar] [CrossRef]
- Atazadegan, M.A.; Heidari-Beni, M.; Entezari, M.H.; Sharifianjazi, F.; Kelishadi, R. Effects of Synbiotic Supplementation on Anthropometric Indices and Body Composition in Overweight or Obese Children and Adolescents: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. World J. Pediatr. 2023, 19, 356–365. [Google Scholar] [CrossRef] [PubMed]
- Ipar, N.; Aydogdu, S.D.; Yildirim, G.K.; Inal, M.; Gies, I.; Vandenplas, Y.; Dinleyici, E.C. Effects of Synbiotic on Anthropometry, Lipid Profile and Oxidative Stress in Obese Children. Benef. Microbes 2015, 6, 775–782. [Google Scholar] [CrossRef] [PubMed]
- Mohammadi, H.; Ghavami, A.; Hadi, A.; Askari, G.; Symonds, M.; Miraghajani, M. Effects of Pro-/Synbiotic Supplementation on Anthropometric and Metabolic Indices in Overweight or Obese Children and Adolescents: A Systematic Review and Meta-Analysis. Complement. Ther. Med. 2019, 44, 269–276. [Google Scholar] [CrossRef]
- Kilic Yildirim, G.; Dinleyici, M.; Vandenplas, Y.; Dinleyici, E.C. Effects of Multispecies Synbiotic Supplementation on Anthropometric Measurements, Glucose and Lipid Parameters in Children With Exogenous Obesity: A Randomized, Double Blind, Placebo-Controlled Clinical Trial (Probesity-2 Trial). Front. Nutr. 2022, 9, 898037. [Google Scholar] [CrossRef]
- Hadi, A.; Arab, A.; Khalesi, S.; Rafie, N.; Kafeshani, M.; Kazemi, M. Effects of Probiotic Supplementation on Anthropometric and Metabolic Characteristics in Adults with Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Clin. Nutr. 2021, 40, 4662–4673. [Google Scholar] [CrossRef]
- Hadi, A.; Alizadeh, K.; Hajianfar, H.; Mohammadi, H.; Miraghajani, M. Efficacy of Synbiotic Supplementation in Obesity Treatment: A Systematic Review and Meta-Analysis of Clinical Trials. Crit. Rev. Food Sci. Nutr. 2020, 60, 584–596. [Google Scholar] [CrossRef]
- Anderson, E.L.; Howe, L.D.; Jones, H.E.; Higgins, J.P.T.; Lawlor, D.A.; Fraser, A. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS ONE 2015, 10, e0140908. [Google Scholar] [CrossRef] [PubMed]
- Puri, P.; Sanyal, A.J. Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup. Clin. Liver Dis. 2012, 1, 99–103. [Google Scholar] [CrossRef]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [Google Scholar] [CrossRef]
- Miele, L.; Marrone, G.; Lauritano, C.; Cefalo, C.; Gasbarrini, A.; Day, C.; Grieco, A. Gut-Liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target. Curr. Pharm. Des. 2013, 19, 5314–5324. [Google Scholar] [CrossRef]
- Chen, J.; Vitetta, L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int. J. Mol. Sci. 2020, 21, 5214. [Google Scholar] [CrossRef] [PubMed]
- Loomba, R.; Seguritan, V.; Li, W.; Long, T.; Klitgord, N.; Bhatt, A.; Dulai, P.S.; Caussy, C.; Bettencourt, R.; Highlander, S.K.; et al. Gut Microbiome-Based Metagenomic Signature for Non-Invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017, 25, 1054–1062.e5. [Google Scholar] [CrossRef] [PubMed]
- Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.; Nobili, V. Randomised Clinical Trial: The Beneficial Effects of VSL#3 in Obese Children with Non-Alcoholic Steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39, 1276–1285. [Google Scholar] [CrossRef] [PubMed]
- Famouri, F.; Shariat, Z.; Hashemipour, M.; Keikha, M.; Kelishadi, R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 413–417. [Google Scholar] [CrossRef]
- Rodrigo, T.; Dulani, S.; Nimali Seneviratne, S.; De Silva, A.P.; Fernando, J.; De Silva, H.J.; Jayasekera; Wickramasinghe, V.P. Effects of Probiotics Combined with Dietary and Lifestyle Modification on Clinical, Biochemical, and Radiological Parameters in Obese Children with Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Randomized Clinical Trial. Clin. Exp. Pediatr. 2022, 65, 304–311. [Google Scholar] [CrossRef] [PubMed]
- Lin, H.; Yip, T.C.-F.; Zhang, X.; Li, G.; Tse, Y.-K.; Hui, V.W.-K.; Liang, L.Y.; Lai, J.C.-T.; Chan, S.L.; Chan, H.L.-Y.; et al. Age and the Relative Importance of Liver-Related Deaths in Nonalcoholic Fatty Liver Disease. Hepatology 2023, 77, 573–584. [Google Scholar] [CrossRef]
- Loomba, R.; Sanyal, A.J. The Global NAFLD Epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 686–690. [Google Scholar] [CrossRef] [PubMed]
- Tailor, A.M.; Peeters, P.H.M.; Norat, T.; Vineis, P.; Romaguera, D. An Update on the Prevalence of the Metabolic Syndrome in Children and Adolescents. Int. J. Pediatr. Obes. 2010, 5, 202–213. [Google Scholar] [CrossRef]
- Friend, A.; Craig, L.; Turner, S. The Prevalence of Metabolic Syndrome in Children: A Systematic Review of the Literature. Metab. Syndr. Relat. Disord. 2013, 11, 71–80. [Google Scholar] [CrossRef]
- Fiore, G.; Pascuzzi, M.C.; Di Profio, E.; Corsello, A.; Agostinelli, M.; La Mendola, A.; Milanta, C.; Campoy, C.; Calcaterra, V.; Zuccotti, G.; et al. Bioactive Compounds in Childhood Obesity and Associated Metabolic Complications: Current Evidence, Controversies and Perspectives. Pharmacol. Res. 2023, 187, 106599. [Google Scholar] [CrossRef] [PubMed]
- Abrahamsson, T.R.; Sinkiewicz, G.; Jakobsson, T.; Fredrikson, M.; Björkstén, B. Probiotic Lactobacilli in Breast Milk and Infant Stool in Relation to Oral Intake during the First Year of Life. J. Pediatr. Gastroenterol. Nutr. 2009, 49, 349–354. [Google Scholar] [CrossRef]
- Laitinen, K.; Poussa, T.; Isolauri, E. Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group Probiotics and Dietary Counselling Contribute to Glucose Regulation during and after Pregnancy: A Randomised Controlled Trial. Br. J. Nutr. 2009, 101, 1679–1687. [Google Scholar] [CrossRef] [PubMed]
- Rautava, S.; Collado, M.C.; Salminen, S.; Isolauri, E. Probiotics Modulate Host-Microbe Interaction in the Placenta and Fetal Gut: A Randomized, Double-Blind, Placebo-Controlled Trial. Neonatology 2012, 102, 178–184. [Google Scholar] [CrossRef]
- Ilmonen, J.; Isolauri, E.; Poussa, T.; Laitinen, K. Impact of Dietary Counselling and Probiotic Intervention on Maternal Anthropometric Measurements during and after Pregnancy: A Randomized Placebo-Controlled Trial. Clin. Nutr. 2011, 30, 156–164. [Google Scholar] [CrossRef] [PubMed]
- Benítez-Páez, A.; Gómez Del Pugar, E.M.; López-Almela, I.; Moya-Pérez, Á.; Codoñer-Franch, P.; Sanz, Y. Depletion of Blautia Species in the Microbiota of Obese Children Relates to Intestinal Inflammation and Metabolic Phenotype Worsening. mSystems 2020, 5, e00857-19. [Google Scholar] [CrossRef]
- Tuovinen, E.; Keto, J.; Nikkilä, J.; Mättö, J.; Lähteenmäki, K. Cytokine Response of Human Mononuclear Cells Induced by Intestinal Clostridium Species. Anaerobe 2013, 19, 70–76. [Google Scholar] [CrossRef]
- Benítez-Páez, A.; Kjølbæk, L.; Gómez Del Pulgar, E.M.; Brahe, L.K.; Astrup, A.; Matysik, S.; Schött, H.-F.; Krautbauer, S.; Liebisch, G.; Boberska, J.; et al. A Multi-Omics Approach to Unraveling the Microbiome-Mediated Effects of Arabinoxylan Oligosaccharides in Overweight Humans. mSystems 2019, 4, e00209-19. [Google Scholar] [CrossRef] [PubMed]
- Kjølbæk, L.; Benítez-Páez, A.; Gómez Del Pulgar, E.M.; Brahe, L.K.; Liebisch, G.; Matysik, S.; Rampelli, S.; Vermeiren, J.; Brigidi, P.; Larsen, L.H.; et al. Arabinoxylan Oligosaccharides and Polyunsaturated Fatty Acid Effects on Gut Microbiota and Metabolic Markers in Overweight Individuals with Signs of Metabolic Syndrome: A Randomized Cross-over Trial. Clin. Nutr. 2020, 39, 67–79. [Google Scholar] [CrossRef] [PubMed]
- Solito, A.; Bozzi Cionci, N.; Calgaro, M.; Caputo, M.; Vannini, L.; Hasballa, I.; Archero, F.; Giglione, E.; Ricotti, R.; Walker, G.E.; et al. Supplementation with Bifidobacterium Breve BR03 and B632 Strains Improved Insulin Sensitivity in Children and Adolescents with Obesity in a Cross-over, Randomized Double-Blind Placebo-Controlled Trial. Clin. Nutr. 2021, 40, 4585–4594. [Google Scholar] [CrossRef] [PubMed]
- Sanchis-Chordà, J.; Del Pulgar, E.M.G.; Carrasco-Luna, J.; Benítez-Páez, A.; Sanz, Y.; Codoñer-Franch, P. Bifidobacterium Pseudocatenulatum CECT 7765 Supplementation Improves Inflammatory Status in Insulin-Resistant Obese Children. Eur. J. Nutr. 2019, 58, 2789–2800. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Borka Balas, R.; Meliț, L.E.; Lupu, A.; Lupu, V.V.; Mărginean, C.O. Prebiotics, Probiotics, and Synbiotics—A Research Hotspot for Pediatric Obesity. Microorganisms 2023, 11, 2651. https://doi.org/10.3390/microorganisms11112651
Borka Balas R, Meliț LE, Lupu A, Lupu VV, Mărginean CO. Prebiotics, Probiotics, and Synbiotics—A Research Hotspot for Pediatric Obesity. Microorganisms. 2023; 11(11):2651. https://doi.org/10.3390/microorganisms11112651
Chicago/Turabian StyleBorka Balas, Reka, Lorena Elena Meliț, Ancuța Lupu, Vasile Valeriu Lupu, and Cristina Oana Mărginean. 2023. "Prebiotics, Probiotics, and Synbiotics—A Research Hotspot for Pediatric Obesity" Microorganisms 11, no. 11: 2651. https://doi.org/10.3390/microorganisms11112651